REG - Diaceutics PLC - Notice of Results

DiaceuticsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250429:nRSc4750Ga&default-theme=true

RNS Number : 4750G  Diaceutics PLC  29 April 2025

Diaceutics - Notice of Results & Presentations

New York, Belfast and London, 29 April 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, will announce its audited final
results for the year ended 31 December 2024 on Tuesday, 13 May 2025.

Analyst Presentation:

A webinar presentation for analysts and investors will be held at 1400 BST
(0900 EDT) on Tuesday, 13 May 2025. Those wishing to attend can register their
interest using the following link:

 

https://us06web.zoom.us/webinar/register/WN_tH4xZK9CR4iL4FkvLAW0bw
(https://us06web.zoom.us/webinar/register/WN_tH4xZK9CR4iL4FkvLAW0bw)

 

Investor Meet Company Presentation:

A webinar presentation for investors will be held via the Investor Meet
Company platform at 1530 BST (1030 EDT) on Tuesday, 13 May 2025. The
presentation is open to all existing and potential shareholders and
registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor
(https://www.investormeetcompany.com/diaceutics-plc/register-investor)

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUWRORVSUSUAR